JP2013513622A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513622A5
JP2013513622A5 JP2012543328A JP2012543328A JP2013513622A5 JP 2013513622 A5 JP2013513622 A5 JP 2013513622A5 JP 2012543328 A JP2012543328 A JP 2012543328A JP 2012543328 A JP2012543328 A JP 2012543328A JP 2013513622 A5 JP2013513622 A5 JP 2013513622A5
Authority
JP
Japan
Prior art keywords
composition
ophthalmic
electrostatic interaction
interaction inhibitor
cation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012543328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060044 external-priority patent/WO2011075430A1/en
Publication of JP2013513622A publication Critical patent/JP2013513622A/ja
Publication of JP2013513622A5 publication Critical patent/JP2013513622A5/ja
Pending legal-status Critical Current

Links

JP2012543328A 2009-12-14 2010-12-13 白内障及び老眼を阻害する方法 Pending JP2013513622A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28613909P 2009-12-14 2009-12-14
US61/286,139 2009-12-14
US35016110P 2010-06-01 2010-06-01
US61/350,161 2010-06-01
PCT/US2010/060044 WO2011075430A1 (en) 2009-12-14 2010-12-13 Methods of inhibiting cataracts and presbyopia

Publications (2)

Publication Number Publication Date
JP2013513622A JP2013513622A (ja) 2013-04-22
JP2013513622A5 true JP2013513622A5 (enExample) 2013-10-17

Family

ID=43532783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543328A Pending JP2013513622A (ja) 2009-12-14 2010-12-13 白内障及び老眼を阻害する方法

Country Status (4)

Country Link
US (2) US8758802B2 (enExample)
EP (1) EP2512492A1 (enExample)
JP (1) JP2013513622A (enExample)
WO (1) WO2011075430A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507209SA (en) 2013-03-14 2015-10-29 Univ Massachusetts Methods of inhibiting cataracts and presbyopia
EP3347368A4 (en) * 2015-09-08 2019-01-23 Viewpoint Therapeutics, Inc. COMPOUNDS AND FORMULATIONS FOR THE TREATMENT OF EYE DISEASES
PE20181070A1 (es) * 2015-11-13 2018-07-04 Univ Massachusetts Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia
CN112040943A (zh) 2018-05-01 2020-12-04 曹季南 可治愈白内障老花眼等的滴眼剂

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) * 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) * 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
JPH0262821A (ja) * 1988-08-27 1990-03-02 Santen Pharmaceut Co Ltd 抗白内障剤
DE3906311A1 (de) * 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
JP2515394B2 (ja) * 1989-03-31 1996-07-10 帝人株式会社 γ―Ｌ―グルタミル―Ｌ―システインエステル誘導体を含有するリポソ―ム製剤
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
DE69027328D1 (de) 1990-12-10 1996-07-11 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur Verwendung in der Medizin
BR9306387A (pt) 1992-05-20 1998-09-15 Senju Pharma Co Agente para tratar catarata e método para a sua preparação
CN1045383C (zh) * 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
JPH09505057A (ja) 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
US5516534A (en) * 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
DE69629230D1 (de) 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
DE69714663T2 (de) 1996-06-28 2003-04-10 Ube Industries, Ltd. Verfahren zur Herstellung von Polybutadien
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) * 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
SK287787B6 (sk) 2000-12-15 2011-09-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Použitie L-karnitínu ako stabilizačného činidla proteínov
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
CN1471924A (zh) * 2003-07-09 2004-02-04 吕家昌 一种有助于老花眼视力恢复的药液
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
WO2005112977A2 (en) 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2005110375A1 (en) 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
EP1814578A2 (en) 2004-11-04 2007-08-08 University of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) * 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20070275098A1 (en) * 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP5685773B2 (ja) * 2007-09-07 2015-03-18 ミート アンド ライブストック オーストラリア リミテッド 血管新生および創傷治癒活性がある薬剤
TW200927100A (en) 2007-10-19 2009-07-01 R Tech Ueno Ltd Pharmaceutical composition for treating cataract
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
JP2011526805A (ja) * 2008-06-30 2011-10-20 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 眼アレルギーの治療に用いる方法及び眼用装置
MY155612A (en) 2008-07-14 2015-11-13 Biocon Ltd A method of synthesizing a substantially monodispersed mixture of oligomers
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CA2831855C (en) 2011-03-31 2019-05-21 Dh Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法

Similar Documents

Publication Publication Date Title
JP2013006877A5 (enExample)
USD818522S1 (en) Pair of eyeglasses
HRP20241239T1 (hr) Novi heterociklički derivati korisni kao shp2 inhibitori
MX2019004468A (es) Uso de lentes de contacto en el tratamiento de una afeccion oftalmologica.
JP2013513622A5 (enExample)
TW200951533A (en) Rotationally stabilized contact lenses and methods for their design
BRPI0606651A2 (pt) telescópio intra-ocular bifocal para correção de baixa visão
EP2951634A4 (en) TRANSPARENT EYE-WIDE DISPLAY WITH EYE RECIPE
WO2017123383A3 (en) Silk-fibroin hydrogels, methods of forming, and uses thereof
BR112014004550A2 (pt) sistema de lentes intraoculares controlado por processador
EP2968973A4 (en) FOR THE EYE IMPROPER LASER RADIATION IN EYE SURGERY
PH12014501719B1 (en) Pyridone derivatives
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
BR112014029510A2 (pt) composição esterilizada e meio aquoso compreendendo, pelo menos, um ácido hialurônico e, pelo menos, um sal hidrossolúvel de sacarose octassulfato, processo de fabricação, e de utilização da mesma, formulação cosméstica, e, kit
USD678391S1 (en) Baroque arms for eyeglasses
ATE511865T1 (de) Ophthalmische zusammensetzungen mit einem carboxylmodifiziertem fructan oder einem salz davon
EP3982879A4 (en) TORIC CONTACT LENS STABILIZING DESIGN BASED ON ORTHOGONAL THICKNESS GRADIENTS AT THE EYELID MARGIN
USD728651S1 (en) Pair of sunglass lens covers
JP2011136980A5 (enExample)
JP2015042663A5 (enExample)
BR112014031443A2 (pt) absorvedores de uv de 2-amino benzofenona para mate-riais de lentes oftálmicas
JP2011098961A5 (enExample)
EA201900332A1 (ru) Очки для водителя
USD700234S1 (en) Clip-on sunglasses
BRPI0814667A2 (pt) Utilização de pelo menos um derivado oxima do 3,5-seco-4-nor-colestano ou um dos seus sais de adição com os ácidos aceitáveis, ou de um dos seus ésteres ou um dos sais de adição dos referidos ésteres com os ácidos aceitáveis.